Mölndal, Sweden, August. 30, 2013

Cellectricon today announces that University College London, UK, has invested in a Cellaxess® Elektra Discovery Platform for neuronal transfection. “After a successful validation, we decided to invest in the Cellaxess Elektra Platform, as it is a truly enabling transfection platform for genomic screening on primary neuronal cultures. We’re excited to continue working with the platform and to use it for new cell types and applications.” Said Robin Ketteler, Group leader, MRC Laboratory for Molecular Cell Biology & University College London. The purchase was funded through an award from the Wellcome Trust and matching funding from UCL.

Cellaxess® Elektra represents a revolutionary concept in automated electric field manipulation of adherent cells. Developed in close collaboration with leading pharmaceutical and biotechnology companies, the platform is highly diverse and can be applied to a wide variety of cellular manipulations in cell biology research. The platform enables in-situ manipulation & monitoring of cell cultures directly in HCA compatible 96- and 384-well microplates at any cellular developmental stage with excellent viability and completely retained cellular morphology.